| PROFILE |
|
| Research and Development: Creating a strong generic pipeline |
|
| At Sun Pharma, we are committed to creating a continually replenished pipeline of speciality generics, included differentiated generics, and registering these across markets. Our research projects are geared to enable us develop the latest molecules and bring them to market, at a reasonable cost. Focused development of generics in defined speciality areas and creating difficult to mimic generics based on complex technologies, is key to our efforts. |
|
| Our first research center, Sun Pharma Advanced Research Center (SPARC), was set up in 1993 in Baroda in the western state of Gujarat in India. The work done here was instrumental for the rapid growth at Sun Pharma. Starting from a small base, the infrastructure at this initially 32,000 sq ft research center was used to streamline product development to bring to market on an average 40 formulations and 25 new API every year. These facilities have since been shifted to our new research campus. |
|
| In 2004, a new research campus with areas for process / product development went on stream in Baroda. His Excellency, Dr. A P J Abdul Kalam, the Hon. President of India, formally inaugurated this research center in a glittering ceremony in December 2004. |
|
| This 16-acre campus with 250,000 sq ft research area offers space for the development of generics meeting international development standards, including difficult to make complex generics and complex API processes, such as those for steroids and peptides. |
|
| This site houses 71 labs that address different aspects of generic dosage form and API development.
A full fledged bioequivalence center spread over 25,000 sq ft and fully equipped with 78 beds works on biostudies for submissions in India and international markets. |
|
| In addition to a wells stocked library and conference areas, spacious and well equipped labs are in place for process chemistry for API development, formulation development for conventional dosage forms and complex delivery systems.
In addition, well-equipped and staffed areas for pharmacokinetics, bioequivalence, and analytical development offer the required support. |
|
 |
|
| A second research center in Mumbai, spread over 50,000 sq ft of floor area, develops generics for the developed markets. This center has developed products for Caraco- most of the products that are marketed by our US subsidiary were developed by this team. This lab works with tight timeframes to support Caraco's new product pipeline. |
|
| Our research commitment for 2006-07 is between 8-10% of the company's turnover and we've put in a total of Rs. 9500 million for research since 1993. Our approach to research has been incremental starting with the simple and moving on to the more complex. We began with simpler dosage forms, then moved on to novel drug delivery systems and complex API. Across areas, 72 patents have been received of 414 patents filed. Every year, we typically bring about 40 new products to the Indian market, scale up 25 API, develop and file for 30 plus ANDAs for the US and 8-10 DMFs for US / Europe. |
|
|
|
